21.8 C
New York
Wednesday, June 10, 2026

Tag: None

newssourceFORcompanyinformationcontent1marketreleases

D2L Inc. Announces Substantial Issuer Bid

TORONTO, June 9, 2026 /CNW/ - D2L Inc. (TSX: DTOL) ("D2L" or the "Company"), a global learning technology company, announced today that the board...

Form 8.5 (EPT/RI) – PPHE Hotel Group Ltd

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY
Rule 8.5 of the Takeover Code (the “Code”

GraniteShares Announces Forward Splits

NEW YORK, June 08, 2026 (GLOBE NEWSWIRE) -- GraniteShares has announced it will execute forward shares split for the several funds (the “Funds”). The total market value of the shares outstanding will not be affected as a result of these splits.

Zoooom Launches Stripe-Powered ‘Secure Payments’ for Private-Party Car Sales

New feature introduces verified wire, card, and Klarna installment options to eliminate...

Shell plc Commences Registered Exchange Offers for Notes Issued in Connection with Prior Private Exchange Offer by Shell Finance US Inc.

Press Release

Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®

REYKJAVIK, Iceland, June 08, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for AVT16, a proposed interchangeable biosimilar to Entyvio® (vedolizumab) lyophilized vial for intravenous administration.

CREDIT AGRICOLE S.A. ANNOUNCES REDEMPTION OF ¥84,200,000,000 Japanese Yen Callable Senior Non-Preferred Bonds issued on June 3, 2021 (ISIN: JP525022AM69)

Montrouge, June 8, 2026

Her Bodhi Claims Evaluated: What Research Reveals About This Primal Queen Alternative, Weight Loss Support and Consumer Reviews

An independent, research-informed evaluation of the Her Bodhi botanical formula — examining its ingredient benefits, weight loss positioning, menopause wellness support, disclosed side effects, and publicly available consumer feedback. 
An independent, research-informed evaluation of the Her Bodhi botanical formula — examining its ingredient benefits, weight loss positioning, menopause wellness support, disclosed side effects, and publicly available consumer feedback.

Pudu Robotics Unveils PuduFM 1.0 and PuduAgent: Defining the Next Era of Humanoid and Embodied AI Systems

Pudu Robotics launches PuduFM 1.0 & PuduAgent, enabling "One Brain, Multiple Embodiments" for scalable service robots across industries.

Twenty-Three Kilometres of Veins in Argentina: Golden Goose Lines Up the Drill

Issued on behalf of Golden Goose Resources Corp. (CSE: GGR) (OTCQB: GGRFF)A junior explorer has finished mapping a sprawling epithermal vein system in Patagonia...

Twenty-Three Kilometres of Veins in Argentina: Golden Goose Lines Up the Drill

Issued on behalf of Golden Goose Resources Corp. (CSE: GGR) (OTCQB: GGRFF)A junior explorer has finished mapping a sprawling epithermal vein system in Patagonia...

America’s Antimony Gap Is Washington’s Problem — and NevGold Is Racing to Help Close It

Issued on behalf of NevGold Corp. (TSXV: NAU) (OTCQX: NAUFF) (Frankfurt: 5E50)With a freshly funded treasury, a 20,000-meter drill program underway and a maiden...

America’s Antimony Gap Is Washington’s Problem — and NevGold Is Racing to Help Close It

Issued on behalf of NevGold Corp. (TSXV: NAU) (OTCQX: NAUFF) (Frankfurt: 5E50)With a freshly funded treasury, a 20,000-meter drill program underway and a maiden...

Form 8.3 -DCC plc

FORM 8.3

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsNone

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers